EUCTR2010-024635-16-CZ进行中（未招募）不适用
A double-blind, double dummy randomised, parallel group, multicentre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged 5 to less than 12 years with moderate to severe persistent reversible asthma.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 498
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and Female subjects 5 to <12 years old.
- •2. Known history of moderate to severe persistent reversible asthma1 for = 6 months prior to the screening visit.
- •3. Demonstrated FEV1 of = 60% to = 90% for predicted normal values (Polgar 1971) during the screening period following appropriate withholding of asthma medications (if applicable):
- •No LABA use within 12 hours and/or no SABA use within 6 hours of the PFT
- •No use of inhaled ICS-LABA asthma therapy within 12 hours of the PFT
- •Inhaled corticosteroids are allowed on the day of screening
- •4. Documented reversibility of = 15% in FEV1 in the screening period
- •5. Current use of an inhaled corticosteroid for asthma at a stable dose for at least 4 weeks prior to the screening visit
- •6. Inadequate asthma control on an ICS alone at a dose of = 500 µg fluticasone equivalents/day, OR controlled asthma on an ICS-LABA combination at a ICS dose of = 200 µg fluticasone equivalents/day
- •7. Demonstrated satisfactory technique in the use of the pMDI and spacer device
- •8. Can perform spirometry adequately
- •9. Willing and able to enter information in the electronic diary with the help of a parent or guardian, if necessary and attend all study visits
- •10. Willing and able to substitute pre-study prescribed inhaled asthma medication for the entire duration of the study
- •11. If a female subject is post menarche a urine pregnancy test may be undertaken at the discretion of the investigator and the subjects? parent(s) /legal representative. This test must be negative.
- •12. Written informed consent and assent obtained as per national laws
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 498
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Near fatal or life-threatening (including intubation) asthma within the past year
- •2. Hospitalisation or an emergency visit for asthma within the past 6 months
- •3. History of systemic (injectable or oral) corticosteroid medication within 1 month of the screening visit
- •4. Current or prior non-response or partial response only to an ICS-LABA combination1
- •5. Evidence of a clinically unstable disease, as determined by medical history, clinical laboratory tests, and physical examination that, in the Investigator?s opinion, preclude entry into the study. Clinically significant” is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study
- •6. In the Investigator?s opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit
- •7. Significant, non-reversible active pulmonary disease (e.g. cystic fibrosis, bronchiecstasis, tuberculosis)
- •8. Known Human Immunodeficiency Virus (HIV)-positive status
- •9. Current smoking history within 12 months prior to the screening visit
- •10. Current evidence of alcohol or substance abuse within 12 months prior to the screening visit
- •11. Subjects who have taken ß- blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrythmics, or potent CYP 3A4 inhibitors such as ketoconazole within 1 week prior to the screening visit
- •12. Current use of medications, other than those allowed in the protocol, that in the investigator?s opinion will have an effect on bronchospasm and/or pulmonary function
- •13. Current evidence of hypersensitivity or idiosyncratic reaction to test medications or components
- •14. Receipt of an Investigational medicinal product within 30 days of the screening visit
- •15. Current participation in a clinical study.
研究者
相似试验
进行中（未招募）
不适用
Comparison of Flutiform, fluticasone and Seretide in treatment of moderate to severe asthma in paediatric patients aged 5 to less than 12 years.Asthma BronchioleMedDRA version: 16.0Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 100000004855EUCTR2010-024635-16-BGMundipharma Research Limited498
进行中（未招募）
不适用
Comparison of Flutiform, fluticasone and Seretide in treatment of moderate to severe asthma in paediatric patients aged 5 to less than 12 years.EUCTR2010-024635-16-PLMundipharma Research Limited498
进行中（未招募）
不适用
Comparison of Flutiform, fluticasone and Seretide in treatment of moderate to severe asthma in paediatric patients aged 5 to less than 12 years.EUCTR2010-024635-16-HUMundipharma Research Limited498
进行中（未招募）
1 期
Study investigating a marketed medicine for asthma - flutiform® (branded name) in patients diagnosed with chronic obstructive pulmonary disease. Neither the doctor nor patient will know the treatment group, which will be established by chance (like flipping a coin). Some of the patients will be treated with flutiform®, while the others will be treated with Atimos®.Chronic obstructive pulmonary disease (COPD)MedDRA version: 16.0Level: LLTClassification code 10010953Term: COPD exacerbationSystem Organ Class: 100000004855EUCTR2012-004162-17-SKMundipharma Research Limited1,530
进行中（未招募）
不适用
Study investigating a marketed medicine for asthma - flutiform® (branded name) in patients diagnosed with chronic obstructive pulmonary disease. Neither the doctor nor patient will know the treatment group, which will be established by chance (like flipping a coin). Some of the patients will be treated with flutiform®, while the others will be treated with Atimos®.Chronic obstructive pulmonary disease (COPD)MedDRA version: 18.1Level: LLTClassification code 10010953Term: COPD exacerbationSystem Organ Class: 100000004855EUCTR2012-004162-17-CZMundipharma Research Limited1,530